Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. A clinically significant effect on verapamil is unlikely as it is metabolised mainly by CYP3A4. No interaction with emtricitabine is expected. However, tenofovir-DF is a substrate of P-gp and inhibitors of P-gp such as verapamil could potentially increase the absorption of tenofovir-DF, thereby increasing the systemic concentration of tenofovir. Monitoring of tenofovir-associated adverse reactions, including frequent renal monitoring, is recommended.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking